Falorni Tech Glass Melting Technology
Banner
Filtraglass

SGD Pharma introduces Clareo

Improved mechanical resistance, significant reduction in the breakage rate and improved inspectability

Clareo is SGD Pharma’s new premium range of moulded glass vials in Type II, for injectable solutions, on show at the Pharmapack exhibition, 7 and 8 February 2018.

Clareo vials from SGD Pharma offer a combination of homogeneous wall thickness and superior cosmetic quality, which for moulded glass Type II is unique in the market. The new range offers technical characteristics similar to the vials in the existing range and can replace them without any regulatory change. Once again, SGD Pharma demonstrates with Clareo its expertise in the control of manufacturing process of moulded glass.
The mission of SGD Pharma, one of the world’s leading manufacturers of glass containers for primary pharmaceutical packaging, is to improve and protect patients’ health by supplying high quality, reliable and innovative glass primary packaging to customers in the pharmaceutical industry. The company’s commitment is to continuously innovate and to reinforce patient safety by improving the physical, chemical and cosmetic properties of its different types of glass.
The mechanical resistance to shock of the Clareo vials has been considerably improved by obtaining a more homogeneous distribution of the glass (+15pts compared to the standard process). This increased regularity allows a significant reduction of the breakage rate (up to 10x lower).
Clareo vials have more flat and uniform bottoms, which ease the thermal transfer during freeze-drying processes.
Clareo vials also offer a superior cosmetic quality, leading to an improved inspectability before and after filling. Pharmaceutical and biotechnology companies benefit from this advantage, allowing a reduction of their Total Cost of Ownership (TCO), mostly for high value-added products.
SGD Pharma can share a list of molecules, for which compatibly with glass Type II has been approved by the authorities.
SGD Pharma is currently the only manufacturer able to supply vials for injectable solutions in moulded glass Type II, offering the combined benefits of transparency and strength.
Clareo is available in capacities of 20, 50 and 100ml in Type II and further developments are in progress. Clareo can also be available, on request, in Type III.
SGD Pharma will present its new products at the Pharmapack exhibition, on 7 and 8 February 2018.

Sign up for free to the glassOnline.com daily newsletter

Subscribe now to our daily newsletter for full coverage of everything you need to know about the world glass industry!

We don't send spam! Read our Privacy Policy for more information.

Share this article
Related news